Syntax Bio

Syntax Bio is a biotechnology company developing a CRISPR-based platform to accelerate and control the differentiation of induced pluripotent stem cells (iPSCs) into therapeutic-grade cells. Their proprietary "Cellgorithm" technology employs a modified CRISPR system to regulate gene expression in a precise, stepwise manner, mimicking natural developmental processes. This approach aims to overcome limitations of traditional methods by reducing differentiation timelines from months to days, enhancing scalability, and lowering manufacturing costs. Syntax Bio collaborates with biopharmaceutical companies, offering its platform to improve the efficiency and accessibility of cell therapy manufacturing.